Frontiers in Immunology (Dec 2022)
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
- Angelina Konnova,
- Angelina Konnova,
- Fien H. R. De Winter,
- Akshita Gupta,
- Akshita Gupta,
- Lise Verbruggen,
- An Hotterbeekx,
- Matilda Berkell,
- Matilda Berkell,
- Laure-Anne Teuwen,
- Greetje Vanhoutte,
- Greetje Vanhoutte,
- Bart Peeters,
- Silke Raats,
- Isolde Van der Massen,
- Sven De Keersmaecker,
- Yana Debie,
- Yana Debie,
- Manon Huizing,
- Pieter Pannus,
- Kristof Y. Neven,
- Kristof Y. Neven,
- Kristof Y. Neven,
- Kevin K. Ariën,
- Kevin K. Ariën,
- Geert A. Martens,
- Marc Van Den Bulcke,
- Ella Roelant,
- Ella Roelant,
- Isabelle Desombere,
- Sébastien Anguille,
- Zwi Berneman,
- Zwi Berneman,
- Maria E. Goossens,
- Herman Goossens,
- Surbhi Malhotra-Kumar,
- Evelina Tacconelli,
- Timon Vandamme,
- Timon Vandamme,
- Marc Peeters,
- Marc Peeters,
- Peter van Dam,
- Peter van Dam,
- Samir Kumar-Singh,
- Samir Kumar-Singh
Affiliations
- Angelina Konnova
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
- Angelina Konnova
- Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
- Fien H. R. De Winter
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
- Akshita Gupta
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
- Akshita Gupta
- Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
- Lise Verbruggen
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- An Hotterbeekx
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
- Matilda Berkell
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
- Matilda Berkell
- Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
- Laure-Anne Teuwen
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
- Greetje Vanhoutte
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Greetje Vanhoutte
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
- Bart Peeters
- Department of Laboratory Medicine, Antwerp University Hospital, Edegem, Belgium
- Silke Raats
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Isolde Van der Massen
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Sven De Keersmaecker
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Yana Debie
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Yana Debie
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
- Manon Huizing
- Biobank, Antwerp University Hospital, Edegem, Belgium
- Pieter Pannus
- Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium
- Kristof Y. Neven
- Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium
- Kristof Y. Neven
- Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium
- Kristof Y. Neven
- Federal Public Service (FPS) Health, Food Chain Safety and Environment, Brussels, Belgium
- Kevin K. Ariën
- 0Virology Unit, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
- Kevin K. Ariën
- 1Department of Biomedical Sciences, University of Antwerp, Edegem, Belgium
- Geert A. Martens
- 2Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium
- Marc Van Den Bulcke
- Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium
- Ella Roelant
- 3Clinical Trial Center (CTC), Clinical Research Centre (CRC) Antwerp, Antwerp University Hospital, University of Antwerp, Edegem, Belgium
- Ella Roelant
- 4StatUa, Center for Statistics, University of Antwerp, Antwerp, Belgium
- Isabelle Desombere
- 5Service Immune response, Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium
- Sébastien Anguille
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
- Zwi Berneman
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Zwi Berneman
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
- Maria E. Goossens
- 6Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium
- Herman Goossens
- Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
- Surbhi Malhotra-Kumar
- Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
- Evelina Tacconelli
- 7Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
- Timon Vandamme
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Timon Vandamme
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
- Marc Peeters
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Marc Peeters
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
- Peter van Dam
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
- Peter van Dam
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
- Samir Kumar-Singh
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
- Samir Kumar-Singh
- Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
- DOI
- https://doi.org/10.3389/fimmu.2022.1062136
- Journal volume & issue
-
Vol. 13
Abstract
BackgroundPatients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti-SARS-CoV-2 immunity in cancer patients has not been proposed.MethodsWe employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune- and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine.ResultsC-reactive protein (general marker of inflammation), interleukin (IL)-15 (a pro-inflammatory cytokine), IL-18 (interferon-gamma inducing factor), and placental growth factor (an angiogenic cytokine) correctly classified patients with a diminished vaccine response assessed at day 49 with >80% accuracy. Amongst these, CRP showed the highest predictive value for poor response to vaccine administration. Importantly, this unique signature of vaccine response was present at different studied timepoints both before and after vaccination and was not majorly affected by different anti-cancer treatments.ConclusionWe propose a blood-based signature of cytokines and growth factors that can be employed in identifying cancer patients at persistent high risk of COVID-19 despite vaccination with BNT162b2. Our data also suggest that such a signature may reflect the inherent immunological constitution of some cancer patients who are refractive to immunotherapy.
Keywords
